PTP22 Inhibitors
PTP22 inhibitors represent a diverse array of chemicals that exert their effects through precise interactions with key signaling pathways. One notable class includes benzyl isothiocyanate (BITC), a direct inhibitor that targets the Ras/ERK pathway by inhibiting MEK, leading to downregulated PTP22 expression. Additionally, 2-amino-5-chlorobenzoic acid indirectly influences PTP22 through modulation of the JNK signaling pathway, disrupting downstream events that impact PTP22.
Trametinib, a selective MEK inhibitor, plays a pivotal role in inhibiting PTP22 by targeting the MAPK pathway. Through specific inhibition of MEK, Trametinib disrupts the signaling cascade that leads to PTP22 activation. The tyrosine kinase inhibitor PP2 directly interferes with PTP22 by inhibiting Src kinases, preventing the phosphorylation and activation of PTP22. A769662, an AMP-activated protein kinase (AMPK) activator, indirectly influences PTP22 by activating AMPK and subsequently inhibiting mTORC1, showcasing a complex interplay between pathways. Sanguinarine, GDC-0941, Nsc-87877, and Rapamycin impact PTP22 through distinct pathways such as NF-κB, PI3K/AKT, direct catalytic inhibition, and mTOR, respectively. Ruxolitinib, a JAK inhibitor, modulates PTP22 through the JAK/STAT pathway, while SB203580, a p38 MAPK inhibitor, indirectly influences PTP22 by targeting p38 MAPK signaling. Niclosamide, an anthelmintic drug, acts as an indirect inhibitor by influencing the Wnt/β-catenin pathway, revealing the diverse strategies employed by this class of chemicals to regulate PTP22 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Benzyl isothiocyanate | 622-78-6 | sc-204641 sc-204641A | 5 g 25 g | $47.00 $156.00 | 1 | |
Benzyl isothiocyanate (BITC) is a potent PTP22 inhibitor that acts by targeting key signaling pathways. Specifically, BITC has been shown to modulate the Ras/ERK pathway. It achieves this by inhibiting the activity of MEK, a crucial kinase within the Ras/ERK cascade. | ||||||
2-Amino-5-chlorobenzoic acid | 635-21-2 | sc-259484 | 10 g | $142.00 | ||
2-Amino-5-chlorobenzoic acid is an indirect inhibitor of PTP22, acting through modulation of the JNK signaling pathway. This compound exerts its inhibitory effects by suppressing the activation of JNK, a kinase associated with diverse cellular processes. Specifically, 2-Amino-5-chlorobenzoic acid interferes with the phosphorylation of c-Jun, a downstream target of JNK. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a selective MEK inhibitor, plays a pivotal role in inhiiting PTP22 by targeting the MAPK pathway. By specifically blocking MEK, an upstream regulator in the MAPK pathway, Trametinib disrupts the signaling cascade that leads to PTP22 activation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2, a tyrosine kinase inhibitor, exhibits inhibitory effects on PTP22 by interfering with Src family kinases. Src kinases are known to phosphorylate and activate PTP22, and PP2 disrupts this process by inhibiting Src activity. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662, an AMP-activated protein kinase (AMPK) activator, indirectly influences PTP22 by targeting AMPK-related pathways. By activating AMPK, A769662 initiates a signaling cascade that leads to the inhibition of mTOR complex 1 (mTORC1). As PTP22 is known to interact with components of the mTOR pathway, the inhibition of mTORC1 by A769662 indirectly affects PTP22 activity. | ||||||
Sanguinarium | 2447-54-3 | sc-473396 | 10 mg | $220.00 | ||
Sanguinarium, a benzophenanthridine alkaloid, acts as a PTP22 inhibitor by impacting the NF-κB signaling pathway. Through its ability to inhibit IκB kinase (IKK), a key regulator of NF-κB activation, Sanguinarine disrupts the canonical NF-κB pathway. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941, a phosphoinositide 3-kinase (PI3K) inhibitor, influences PTP22 activity by targeting the PI3K/AKT pathway. By inhibiting PI3K, GDC-0941 disrupts the activation of AKT, a downstream effector of PI3K. | ||||||
NSC 87877 | 56990-57-9 | sc-204139 | 50 mg | $137.00 | 12 | |
NSC-87877, a pyrazolopyrimidine derivative, serves as a PTP22 inhibitor by directly targeting the enzyme. This small molecule inhibits PTP22 by binding to its catalytic site, preventing the dephosphorylation of its substrates. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences PTP22 by targeting the mTOR signaling pathway. Through its interaction with the FK506-binding protein (FKBP), Rapamycin inhibits mTOR complex 1 (mTORC1) activity. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a Janus kinase (JAK) inhibitor, influences PTP22 by targeting the JAK/STAT signaling pathway. By specifically inhibiting JAK1 and JAK2, Ruxolitinib disrupts the downstream activation of STAT proteins. | ||||||